Skip to main content

Table 2 Meta-regression models for achieving 70% of American College of Rheumatology response at total of study duration (mean = 14 months) as dependent variable

From: Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis

 

RR

95% CI

p

Lower bound

Upper bound

Model 1

Mean baseline HAQ (each additional 0.1 point)

2.0433

1.0328

14.4460

0.028

Model 2

Background TNFi in control arm (yes vs no)

0.3166

0.1345

07460

0.009

Model 3

Follow-up time (each additional 1 month)

0.9714

0.9522

0.9920

0.007

Model 4

Mean baseline HAQ (each additional 0.1 point)

2.0332

1.0141

14.6164

0.045

Background TNFi in control arm (yes vs. no)

0.2187

0.1341

0.3567

 < 0.001

Follow-up time (each additional 1 month)

0.9763

0.9504

0.9899

0.016

ABA versus RTX

1.7736

0.1134

10.2165

0.625

ABA versus TCZ

2.2171

1.5541

3.1614

 < 0.001

  1. RR relative risk; HAQ Health Assessment Questionnaire score; TNFi tumor necrosis factor inhibitors; ABA abatacept; RTX rituximab; TCZ tocilizumab; ACR70 70% of American College of Rheumatology
Back to article page

Advances in Rheumatology

ISSN: 2523-3106